Efficacy of Sana Treatment in Fibromyalgia

Inclusion criteria

• Willing to and capable of providing written informed consent prior to the conduct of any study-related procedures.
• Male or female, 18 to 65 years of age, inclusive.
• Clinical diagnosis of Fibromyalgia given a minimum of 8 weeks prior to Screening.
• Patient must have an average pain severity score of ≥40 and <90 on the 100-point VAS for the last 72 hours prior to Screening.
• Any analgesic therapy must be at approximately stable levels for at least 14 days prior to enrollment and remain steady throughout the study.
• Willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the Treatment Phase.
• Able to understand, speak and read English sufficient for the completion of study assessments.

Exclusion criteria

• Pregnant or lactating females as self-reported.
• History or presence of photo-sensitive epilepsy or other photo-sensitive conditions.
• History or presence of condition(s) that may affect balance, such as seizure disorders or vertigo.
• Diagnosis of cancer or active cancer treatment occurring within the last year.
• Surgery or trauma requiring rehabilitation within the last 12 weeks.
• Vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes, at the discretion of the investigator.
• Deafness in one or both ears, perceived differences in hearing between ears, or tinnitus, at the discretion of the investigator.
• Current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion).
• Presence of inflammation or broken skin around the eyes in the area of the mask.
• Presence of narcolepsy or untreated sleep apnea or requiring treatment for sleep apnea such that use of device at bedtime will be interrupted, at discretion of the investigator.
• Participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days.
• Any pending legal action that could prohibit participation or compliance in the study.
• Recent history of or current evidence of suicidal ideation or active suicidal behavior, based on medical history, at the discretion of the investigator.
• Significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the patient from safely participating in study.